Get the Daily Brief
Latest Biotech News
Guardant inks Zephyr AI pact: multimodal genomics meets machine learning
Guardant Health entered a strategic partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its genomic testing platforms with Zephyr’s AI and machine‑learning analytics to...
Zag Bio emerges with $80M: thymus-targeted Treg approach for autoimmunity
Zag Bio launched from stealth with roughly $80 million in disclosed funding to develop bifunctional antibodies that deliver tolerizing antigens to the thymus and induce regulatory T cell (Treg)...
Intellia pauses CRISPR trials—liver toxicity hospitalizes patient
Intellia Therapeutics paused enrollment and dosing in two late‑stage trials after a volunteer receiving its CRISPR candidate for transthyretin amyloidosis was hospitalized with severe liver...
Novartis buys Avidity: $12 billion deal expands RNA neuromuscular push
Novartis announced it will acquire Avidity Biosciences for roughly $12 billion to add three late‑stage antibody‑oligonucleotide conjugate (AOC) programs and Avidity’s muscle delivery platform to...
Lilly, Nvidia to build pharma supercomputer—AI-driven drug design scale-up
Eli Lilly partnered with Nvidia to construct what the companies say will be the most powerful supercomputer owned and operated by a pharmaceutical firm, aimed at training large AI models for drug...
GSK licenses Empirico siRNA—$85M upfront to broaden COPD pipeline
GSK paid $85 million up front for global rights to Empirico’s Phase‑1 siRNA candidate (EMP‑012) targeting inflammatory drivers of COPD and other respiratory diseases. The agreement gives GSK...
Electra raises $183M—pivotal trial starts for rare hyperinflammation drug
Electra Therapeutics closed an oversubscribed $183 million Series C to fund a global pivotal trial of ELA026, its monoclonal antibody candidate for secondary hemophagocytic lymphohistiocytosis...
Zag Bio launches: $80M to develop thymus‑targeted tolerizing therapies
Zag Bio emerged from stealth with $80 million in disclosed funding to advance bifunctional antibodies that traffic tolerizing antigens to the thymus and promote regulatory T cell (Treg)...
FDA allows at‑home dosing: Delix to test non‑hallucinogenic neuroplastogen
The FDA cleared at‑home administration for Delix Therapeutics’ next Phase‑2 study of a non‑hallucinogenic 'neuroplastogen' being developed for depression. Delix reported promising early clinical...
Haystack MRD debuts: ultrasensitive ctDNA test for post‑surgical surveillance
Haystack Oncology, part of Quest Diagnostics, launched Haystack MRD®, a tumor‑informed circulating tumor DNA (ctDNA) workflow designed to detect minimal residual disease (MRD) with high...
Guardant, Zephyr AI partner—multimodal data to accelerate biomarker discovery
Guardant Health struck a strategic partnership with Zephyr AI to combine Guardant’s large multimodal molecular datasets with Zephyr’s AI and machine learning platform to accelerate discovery of...
Hybrid gRNAs improve adenine base editing—better on‑target edits, lower off‑targets
A University of Pennsylvania team reported that hybrid guide RNAs—gRNAs with select DNA nucleotide substitutions—boost adenine base editor (ABE) performance by reducing off‑target and bystander...
Novartis buys Avidity for $12B – RNA delivery play expands neuroscience portfolio
Novartis agreed to acquire Avidity Biosciences in a deal valued at roughly $12 billion to add three late‑stage antibody‑oligonucleotide conjugate (AOC) programs and a proprietary muscle‑delivery...
Intellia halts two CRISPR trials after severe liver event: enrollment paused
Intellia Therapeutics paused enrollment and dosing in two late‑stage trials of its in vivo CRISPR program (nex‑z) after a trial volunteer was hospitalized with life‑threatening liver toxicity. The...
GSK acquires Empirico siRNA for COPD – $85M upfront, broad respiratory ambitions
GSK struck a deal to license EMP‑012, an Empirico‑discovered small‑interfering RNA (siRNA) in Phase 1 for chronic obstructive pulmonary disease (COPD), paying $85 million upfront with potential...
Lilly and Nvidia to build pharma’s most powerful supercomputer – AI for drug discovery
Eli Lilly and Nvidia announced a partnership to build what they described as the most powerful supercomputer operated by a pharmaceutical company, aimed at training large AI models for drug...
FDA allows Delix at‑home dosing in next study – non‑hallucinogenic neuroplastogen advances
Delix Therapeutics said early clinical data for its non‑hallucinogenic neuroplastogen showed promise in depression, and the FDA cleared the company to permit at‑home dosing in its upcoming Phase 2...
Zag Bio launches with $80M to engineer thymus‑targeted tolerance medicines
Zag Bio emerged from stealth with $80 million in financing and a platform that aims to induce immune tolerance by delivering bifunctional antibodies to the thymus, the organ that produces...
Hemab raises $157M to pursue coagulation disorder pipeline – sutacimig pivotal next
Hemab Therapeutics closed a $157 million financing to advance a portfolio of programs addressing rare coagulation disorders, including plans to start a pivotal trial of sutacimig in Glanzmann...
BridgeBio to push for approval after positive limb‑girdle Phase 3 readout
BridgeBio reported an encouraging Phase 3 interim readout for ribitol in limb‑girdle muscular dystrophy type 2I/R9 and said it will meet with the FDA to discuss regulatory plans and potential...